Well I'll be dipped in #$%$. Might not be a bad thing though. Something seemed to be happening on the bull side this week and there's surely a connection. Maybe. :)
Y'all see this ? This many companies working on it makes me think that if Xoma wins this race it'll be a bigger deal than expected.
This report provides comprehensive information on the therapeutic development for Uveitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Uveitis and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
Advanced Cell Technology, Inc.
Santen Pharmaceutical Co., Ltd.
Apitope International NV
Enzo Biochem, Inc.
Can-Fite BioPharma Ltd.
HanAll Biopharma Co., Ltd.
to-BBB technologies BV
Janssen Biotech, Inc.
Icon Bioscience, Inc.
Panoptes Pharma Ges.m.b.H.
Stem Cell Therapy for Ophthalmic and Autoimmune Diseases
plastoquinone decyl triphenylphosphonium bromide
Small Molecules to Inhibit Kinase for Uveitis and IBD
Drugs to Inhibit Aldose Reductase for Immunology, Ophthalmology, Metabolic, Respiratory and Autoimmune Disor
ravice I think the success of the phase 3 eye stuff is a given and that's why it got over $9 in the first place. Then the problems that arose with the FDA wanting them to use a higher threshold, and the delay in signing up people because of this knocked it back. Plus the Baker Brothers filing made everybody nervous. But the last presentation was so positive I feel that a lot of the loss should be made up before any official announcement comes. I think that last sale was probably for a good reason and not an omen but it is certainly a negative isn't it.
XOMA Corp (NASDAQ:XOMA) CMO Paul D. Rubin sold 26,748 shares of the stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $4.34, for a total transaction of $116,086.32. Following the completion of the sale, the chief marketing officer now directly owns 72,021 shares in the company, valued at approximately $312,571.
I'm sorry but we are spending all our time wondering if Xoma could go to $1.50.
Hi Onyx. We've suffered enough. Time to start another manic cycle.
No. It just happens occasionally with no real follow through. Another day like that today, with heavier volume, will get our attention.